Changes in Bone Density in Carriers of BRCA1 and BRCA2 Pathogenic Variants After Salpingo-Oophorectomy
Chan, Leslie N. MD; et al (Obstetrics & Gynecology 142(1):p 160-169, July 2023. | DOI: 10.1097/AOG.0000000000005236) evaluated the effect of risk-reducing salpingo-oophorectomy (RRSO) on change in bone mineral density (BMD) in women aged 34–50 years with pathogenic variants in BRCA1 or BRCA2 (BRCA1/2) using The PROSper (Prospective Research of Outcomes after Salpingo-oophorectomy) study, a prospective cohort of women aged 34–50 years with BRCA1 or two germline pathogenic variants
Of 100 PROSper participants, 91 obtained DXA scans (RRSO group: 40; non-RRSO group: 51).
The authors concluded that women with pathogenic variants in BRCA1/2 who undergo RRSO before the age of 50 years have greater bone loss after surgery that is clinically significant when compared with those who retain their ovaries. Hormone use mitigates, but does not eliminate, bone loss after RRSO. These results suggest that women who undergo RRSO may benefit from routine screening for BMD changes to identify opportunities for prevention and treatment of bone loss.